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Ventricular arrhythmia and subsequent sudden cardiac death (SCD) due to acute
myocardial infarction (AMI) is one of the most frequent causes of death in humans. Lethal
ventricular arrhythmias like ventricular fibrillation (VF) prior to hospitalization have been
reported to occur in more than 10% of all AMI cases and survival in these patients
is poor. Identification of risk factors and mechanisms for VF following AMI as well as
implementing new risk stratification models and therapeutic approaches is therefore
an important step to reduce mortality in people with high cardiovascular risk. Studying
spontaneous VF following AMI in humans is challenging as it often occurs unexpectedly
in a low risk subgroup. Large animal models of AMI can help to bridge this knowledge
gap and are utilized to investigate occurrence of arrhythmias, involved mechanisms and
therapeutic options. Comparable anatomy and physiology allow for this translational
approach. Through experimental focus, using state-of-the-art technologies, including
refined electrical mapping equipment and novel pharmacological investigations, valuable
insights into arrhythmia mechanisms and possible interventions for arrhythmia-induced
SCD during the early phase of AMI are now beginning to emerge. This review describes
large experimental animal models of AMI with focus on first AMI-associated ventricular
arrhythmias. In this context, epidemiology of first AMI, arrhythmogenic mechanisms and
various potential therapeutic pharmacological targets will be discussed.
Keywords: acute myocardial infarction, ventricular arrhythmia, animal models, anti-arrhythmia agents, sudden
cardiac death, STEMI, ischemia, ventricular fibrillation
INTRODUCTION
Despite a decrease in overall cardiovascular mortality over the past decades, ∼17 million deaths
a year occur worldwide as a result of cardiovascular disease (1) and ∼50% of these are reported
to be sudden cardiac deaths (SCD) (2). In the elderly, constituting the major age group at risk,
SCD is often associated with chronic degenerative diseases, such as coronary artery disease (with
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acute myocardial infarction (AMI) as its ultimate consequence),
valvular diseases, and heart failure.
In the early stages of AMI ventricular fibrillation (VF) is a
frequent cause of SCD, which often occurs within minutes after
onset of clinical symptoms, often even before the patient has
established contact to medical health care systems. As out of
hospital VF following AMI is sudden and unexpected, only sparse
information concerning risk factors and protective mechanisms
are available from human studies.
Hence, to understand the mechanisms of ventricular
arrhythmias developing during AMI and to discover new
treatment modalities for these patients, investigations through
translational experimental models, mimicking the clinical
situation, are needed. While numerous experimental models of
myocardial infarction exist, most of them focus on mechanisms
and on options to prevent manifestation and expansion of
infarction and scar formation in order to improve tissue survival
in post-AMI patients. Only a relatively limited number of studies
focus on the acute arrhythmogenic risk of AMI. This in spite
of the fact, that there is a critical need for fast acting acute
antiarrhythmic treatments in AMI patients. Treatment that is
safe to use on site or in an ambulance without severe negative
hemodynamic or proarrhythmic adverse effects. Hence, there is
an unmet medical need for such therapeutic options, which calls
for investigations of novel pharmacological targets in clinical and
preclinical antiarrhythmic research.
This review will present the published literature on
experimental large animal models of AMI with focus on
translatability to the epidemiology of first AMI-associated
ventricular arrhythmias. Various therapeutic pharmacological
targets will be discussed in this context. Along with this, a brief
overview of the involved arrhythmogenic mechanisms leading to
VF during AMI is given.
ACUTE MYOCARDIAL INFARCTION AND
SUDDEN CARDIAC DEATH
Ischemia-related VF is by far the leading cause of sudden
cardiac arrest and the most frequent occurring arrhythmia in
SCD (2–5). In AMI, occlusion of a coronary artery induces
an imbalance between oxygen supply and demand leading to
ischemia-induced cell death of cardiac myocytes. Transmural
AMI, seen as ST-elevation myocardial infarction (STEMI) in
the electrocardiogram (ECG) is present in 25–40% of all AMI
cases (6). AMI rapidly changes electrophysiological properties
of the ventricular myocardium and, in a significant proportion
of patients, promote electrical disturbances in conduction and
repolarization, leading to ventricular tachycardia (VT) or VF and
subsequently cardiac arrest (Figure 1) (6). Due to development of
myocardial scar tissue and heart failure, ventricular arrhythmias
and subsequent SCD can still occur after transition from acute to
chronic myocardial infarction.
By nature, it is difficult to establish the cause of death to be
VF caused by AMI when it happens out of hospital. The numbers
in the following studies likely underestimate the true burden of
VF during first AMI because individuals experiencing SCD are
not reported. Many patients with ischemia-induced VF will be
found dead, or, after being resuscitated, die or survive with or
without neurological sequelae (8, 9). Even if medical contact is
established, only 4.3–19.4% of the patients experiencing out-of-
hospital cardiac arrest (OHCA) survive the first 30 days (8). In
patients with STEMI, 30-days survival decreases from 94% in
patients without VF to 79% in those with VF (10). In our own
Danish nationwide prospective case-control study, the GEVAMI
(GEnetic causes of Ventricular Arrhythmias in patients with
first ST-elevation Myocardial Infarction) study, we enrolled 660
consecutive STEMI patients and found 11.6% to develop VF
before primary PCI (11). The French e-MUST (Evaluation en
Médecine d’Urgence des Stratégies Thérapeutiques des infarctus
du myocarde) study reported that 5.6% of patients with STEMI
experienced VF witnessed by emergency medical service (EMS)
on site. Of these patients, 9.1% died out-of-hospital and a further
29% in-hospital (12).
Myocardial Infarction and VF Risk
The assessment of risk factors of VF due to AMI is non-trivial:
Studies must be designed to distinguish between risk factors
for AMI without VF and those for AMI with VF. Further,
patients suffering from SCD before AMI is diagnosed are often
not included in such studies. Finally, these events occur in low
risk subgroups without any known risk factors, like structural
heart disease (4). Possible risk factors for VF can either be
present before AMI takes place or can be directly associated with
specific factors of the AMI itself. The former are determined by
heritability, comorbidity, medication, lifestyle, and gender, while
the latter, mostly observed as changes in the ECG, includes infarct
size and location of coronary obstruction, as well as individual
ventricular and coronary anatomy (11, 13).
Pre-AMI Risk Factors
The Dutch AGNES (Arrhythmia Genetics in the Netherlands)
study was the first designed to differentiate between risk factors
for AMI in general and AMI complicated by VF (13). This
study compared first AMI patients who developed VF with
AMI patients without VF. Those with VF had a family history
of SCD, a lower body mass index, and a lower prevalence of
hypercholesterolemia and diabetes compared to controls.
The GEVAMI study compared first STEMI with and without
VF and was able to identify several independent risk factors for
VF including age below 60 years, family history of SCD, absence
of pre-infarction angina, use of statins, history of atrial fibrillation
(AF) and alcohol intake (> 7 units per week) (11). Whereas,
alcohol has favorable effects on the development of thrombosis
and atherosclerosis and lowers the risk of AMI (14), a u-shaped
relationship exists in SCD. A moderate consumption of alcohol
(2–6 units a week) reduces the risk for SCD (15, 16), while higher
alcohol intake increases the risk (17).
Several studies support the theory that a genetic predisposition
to SCD and VF exists in the setting of AMI (13, 18). A family
history of SCD among siblings or parents increased the risk of VF
(odds ratio of 1.6–3.2) (11, 13, 19). However, little is known about
the specific genetic factors affecting VF during AMI. A genome
wide association study (GWAS) in the AGNES study cohort
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FIGURE 1 | ECG tracings during acute myocardial infarction (AMI) in a porcine model. At baseline, sinus rhythm is present with P wave (green), QRS complex (purple),
ST segment (red) and T wave (orange). AMI leads to elevation of the ST segment (red arrow), depression of the TQ segment (blue arrow) followed by T wave alternans
(asterisk, note the alternating morphologies). In this example, ventricular fibrillation is triggered by two short coupled ectopic beats (turquoise). Dotted line, 0mV.
Reproduced with permission from Sattler (7).
revealed a strong association between VF during AMI and a gene
locus near the CXADR gene, that encodes for the coxsackie-
and adenovirus receptor (20). Smaller studies point at genetic
variations in the SCN5A gene, coding for the cardiac sodium
channel Nav1.5, as a predisposing factor for the development of
VF upon AMI (21). Epidemiology and genetics of VF in AMI
have been reviewed recently by Glinge et al. (22).
Another important confounder to VF in AMI is AF (11,
13). Data from the FAST-MI (French ST-elevation and non-
ST-elevation Myocardial Infarction) 2005 registry point at AF
observed on the initial ECG obtained during STEMI to be
an independent risk factor for early VF (odds ratio 2.5) (23).
Increased heart rate in AF can shorten ventricular refractoriness
creating a substrate for VF (24). Additionally, this proarrhythmic
substrate can be aggravated by hemodynamic changes that
can decrease parasympathetic and increase sympathetic tone in
AF (25).
AMI Risk Factors
Properties of AMI itself including infarct size and location
can alter the incidence of VF. Electrocardiograms obtained in
the early phase of AMI are therefore not only important for
diagnosing AMI, but also in early risk stratification. Patients
presenting with high ST elevation score (11, 26), short RR
intervals (27) or prolonged PR and QRS intervals (26) in
their ECGs carry a higher risk of VF. Additionally, patients
with ST-segment elevation accompanied with distortion of
the terminal QRS complex had increased ischemia burden,
faster progression of necrosis (28), and a higher risk of
VF (26).
Incidence of VF is also influenced by the affected artery
or arteries. A Belgian case-control study, investigating cardiac
arrest, found an increased risk of out-of-hospital VF in patients
with acute occlusion on the left coronary artery (left anterior
descending (LAD) or left circumflex (LCx) artery) compared
to the right coronary artery. However, the exact occlusion site
(proximal or distal part) within the left coronary artery did not
affect VF burden (29). Similar results were found in the Dutch
AGNES study (13). This is somehow conflicting as proximal
occlusion sites result in larger areas of myocardium at risk and
have been shown to be a risk factor in animal models (30, 31).
Reasons for these discrepancies could be manifold including time
to reopening of the occluded vessel, residual flow in the coronary
artery, or the limited number of patients.
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CARDIAC ELECTROPHYSIOLOGY AND
ARRHYTHMOGENESIS
AMI causes a variety of electrophysiological changes generating
triggering factors and a proarrhythmic substrate that can
induce and sustain VF. In this section we give a brief
introduction to important concepts on cardiac electrophysiology
and arrhythmogenesis during ischemia. For a more in depth
review we refer to the reviews by Janse and Wit (32) and
Carmeliet (33).
The cardiac action potential (AP) is formed following fine-
tuned temporal and spatial openings of depolarizing sodium
(Na+) and calcium (Ca2+) and repolarizing potassium (K+)
channels (Figure 2, left) (34). AMI alters the metabolic state
(mainly via acidosis and ATP depletion) and causes electrical
changes in both the ischemic area and the border zone between
the ischemic and non-ischemic area. Numerous factors have been
proposed to support the generation of arrhythmias: The resting
membrane potential is depolarized, conduction velocity in the
ventricles slows down, and AP duration shortens by alterations in
the K+ and Cl− currents during AMI (Figure 2, right) (32, 35).
During ischemia three underlying mechanisms, automaticity,
triggered activity, and reentry can be involved in inducing
or sustaining arrhythmias (premature beats, VT and VF;
Figure 3) (33). Automaticity is caused by myocardial stretch,
or short-circuit and injury currents in the border zone
leading to spontaneous depolarizations outside the sinus
node. Triggered activity is caused by Ca2+ overload in
Purkinje fibers or cardiomyocytes. The Purkinje system is
thought to play a role in the transition of a stable reentrant
VT into VF by rapid and irregular conduction of reentrant
waves into non-ischemic tissue (36). Finally, reentry is
caused by wave fronts following a pathway around an area
of unidirectional block and reexcitement of previously
activated cardiomyocytes instead of dying out. Reentry
occurs in the presence of a functional disturbance in impulse
conduction and heterogeneity in conduction as present during
AMI (32).
Early studies on VF used rather simplified concepts to
explain VF initiation, including a single stable reentry circuit
traveling along an anatomical obstacle or the leading circle
theory in which a wave front travels around a functional
obstacle that is constantly kept depolarized (37). Rotors, a
form of functional reentry where the curved wave front and
wave tail meet each other in an excitable singularity, have
emerged as an explanatory theory for VF in the last decades:
A propagating wave front with a curvature R (source) travels
along an obstacle (for example an unidirectional block) and
is about to enter excitable but non-excited tissue (sink). The
curvature R is dependent on electrophysiological properties like
conduction velocity. At the edge of the obstacle, the curvature
R determines whether the wave will detach from the obstacle
or follow it. If R is smaller than the critical radius of the
obstacle, the wave will eventually detach, curl and rotate around
its broken tip (37). In VF initiation and maintenance, a small
number of driving rotors (mother rotor) and multiple wavelets
have been detected in humans with VF and are thought to be
important (38).
Autonomic imbalance, characterized by increased
sympathetic activation and parasympathetic withdrawal,
may also contribute to the early manifestation of ventricular
arrhythmia in the acute phase of AMI as well as following
AMI (39, 40).
Arrhythmias During Ischemia
Changes in ionic currents and the development of an arrhythmic
substrate during early AMI have a defined time course and
ventricular arrhythmias (premature beats, VT and VF) occur in
two distinct phases, 1a and 1b (32, 41).
FIGURE 2 | Cardiac action potential in normal and ischemic myocardium. (Left) Action potential with depolarizing sodium (INa), transient outward potassium (Ito),
calcium (ICa), and repolarizing potassium (IK ) currents. (Right) During ischemia conduction is slowed, the resting membrane potential depolarized and action potential
duration (APD) is shortened. [Na+]i, intracellular sodium concentration, [K
+]o extracellular potassium concentration, IK,ATP, ATP-sensitive potassium current. Modified
with permission after Sattler (7).
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FIGURE 3 | The three mechanisms, automaticity (A), triggered activity (B), and reentry (C) can play a role in arrhythmogenesis during ischemia. (A) Injury current
across the border zone leading to ST elevation in the electrocardiogram, (B) Triggered activity mainly caused by Ca2+ overload in cardiomyocytes or Purkinje fibers.
(C) Reentry. Electrical activation wave front (1) is deflected at the border zone due to unidirectional block (T) into two wave fronts (2), eventually passing the border
zone (3) and exciting the infarct zone (4) and finally passing the unidirectional block re-exciting the area in front of the block (5). Ito, transient outward potassium
current; [K+]o, extracellular potassium concentration; [Na
+]i, intracellular sodium concentration. Reproduced with permission from Sattler (7).
Phase 1a takes place between 2 and 10min after AMI and is
induced by focal activation due to injury currents in a substrate of
profound slowing in conduction velocity and delayed activation
due to decreased resting membrane potential (41). Reentry is the
predominant mechanism during this phase, but triggered activity
can also be involved in the generation of premature beats (32, 42).
Phase 1b occurs 18–30min after coronary occlusion.
Arrhythmias are likely related to mechanical stretch in the
border zone, increased catecholamine levels and cellular
uncoupling (43–45).
Overall incidence of arrhythmias is higher during phase 1a
while VF occurs more often during phase 1b (46). Data in
humans on the importance of phase 1a and 1b on SCD are scarce,
since ECG recordings in patients are rare, while animal models
suggest larger mortality in phase 1b than in phase 1a (47–49).
ANIMAL MODELS OF VENTRICULAR
ARRHYTHMIAS IN ACUTE ISCHEMIA
Animal models are essential in understanding the mechanisms
of identified risk factors on arrhythmogenesis and subsequent
SCD. Mimicking the exact pathophysiological conditions in
experimental models translatable to AMI in humans can be
challenging. Ideally the experimentally-induced AMI results in
the same pathophysiological changes that would be expected
in a diseased human, however, experiments in smaller animals
have limitations in translatability to humans. This is mainly
due to differences in the dimensions of the ventricles, the heart
and the cardiovascular system as a whole, the morphology and
duration of the AP, as well as differences in hemodynamic and
cardiac electrophysiological responses to ventricular ischemia
(50). In contrast, large animal models provide a better
opportunity to study the pathophysiology and pathogenesis
of AMI and associated arrhythmias (32) and allow the use
of established invasive techniques also applied in the clinic,
such as coronary angiograms, multisite electrogram recordings,
stimulation protocols, electrode arrays, or whole electrode
mapping-socks covering the entire heart (51, 52).
Besides the applied species, the occurrence of studied
ventricular arrhythmias depends on a number of factors,
including anesthetic regimen, mode of coronary occlusion,
occlusion site and size of the ischemic area, coronary collaterals,
and the regulation of the autonomic nervous system.
Anesthesia
The vast majority of animal models developed for understanding
AMI-induced ventricular arrhythmias have concerned fully
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anesthetized animals, although, notable differences can be
observed between conscious and anesthetized animals (53).
Numerous different anesthetic drug-regimens have been used, as
reviewed by Hamlin (54). Anesthetics have different abilities to
sustain an adequate anesthesia but often come with unwanted
effects on susceptibility of ventricular arrhythmias, sympathetic
and parasympathetic regulation, and on the cardiovascular
system itself.
Briefly, many studies investigating arrhythmias in
animals have used barbiturates. These drugs have strong
parasympatholytic effects, reducing transmural dispersion
of ventricular repolarization (55), leading to a less frequent
occurrence of ventricular arrhythmias (56, 57). A comparison
of the volatile anesthetics isoflurane and sevoflurane in pigs
revealed a higher VF and mortality rate in the isoflurane
group (58). Propofol is an anesthetic drug acting mainly on
the gamma-aminobutyric acid (GABA) receptor and is widely
used nowadays as it is easy to dose. It comes with notable
effects on hemodynamics, including reduced cardiac output,
venous return, systemic pressure, and vascular resistance
(59). In studies that investigate autonomic regulation of the
cardiovascular system and effects of cardiovascular drugs the
use of morphine and alpha chloralose (60, 61) or urethane and
alpha chloralose (62) might be considered. The use of morphine
and alpha chloralose has lower effects on the cardiovascular-
and autonomic nervous system compared to other regimens and
create a state comparable to sleep (63). Thus, when the focus is
placed on assessing risk predictors and effects of antiarrhythmic
treatments, the effects of the used anesthetic regimen must be
taken into account.
Mode of Infarct Induction
A response similar to AMI caused by atherosclerosis or
thromboembolic events in otherwise healthy hearts can be
provoked by occluding a coronary artery in an experimental
animal. This can be performed surgically by coronary vessel
ligation in an open chest configuration (Figure 4A) or,
less invasively, by catheter based techniques in closed-chest
models including percutaneous balloon occlusion (Figure 4B)
or microsphere injection (65, 66). Surgical ligation and
balloon occlusion allow for ischemia/reperfusion models and
correspond to transmural myocardial infarction seen as STEMI
FIGURE 4 | (A) Open chest approach. Visualization of a heart from a Danish Landrace pig after mid-thoracotomy in anterior-posterior view. Right (RA) and left atrium
(LA), right (RV), and left ventricle (LV) as well as the left anterior descending artery (LAD) with its diagonal branch (D1) are visible. Pericardium (PC) is opened, allowing
the dissection of the LAD, a silk snare with a counter bearing (asterisk) is placed around the artery (arrowhead, round magnification) and tightened for coronary
occlusion. For more stable hemodynamic conditions the thorax is closed to a minimum. (B) Closed chest approach presenting an angiogram of a pig heart of the left
coronary artery with LAD and left circumflex artery (LCx) in anterior-posterior view. Anatomical details of the coronary arteries can be identified. Placing a percutaneous
transluminal coronary angioplasty (PTCA) balloon and inflating this leads to an occlusion downstream the LAD, here shown for a mid-LAD occlusion. RA, Right atrium;
LA, Left atrium. Yellow area indicates area at risk during ligation/occlusion. Modified with permission after Sattler (7) and Sattler et al. (64).
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in patients (67). Microspheres induce local clotting in the heart
microcirculation and lead to subsequent chronic myocardial
ischemia (66). These techniques model AMI, the ultimate
consequence of coronary artery disease. Less distinctive effects
of coronary artery disease preceding AMI, including marginal
effects of heart failure with chronic remodeling of autonomic
innervation, inflammatory activation with its direct effect on the
arrhythmic substrate (68), as well as development of collaterals
are often missed.
The development of canine and porcine infarct models started
with two-staged open chest models. A coronary artery was
occluded to 50% of its diameter and occlusion was kept for
30min before the artery was occluded completely and transmural
AMI was induced (65, 69). These two-staged experiments often
showed decreased arrhythmias and infarct size, most likely due
to myocardial preconditioning (70). Two-staged models can be
used to mimic the correlate of pre-infarction angina. Schwartz
et al. moved from modeling the “healthy” human heart with
first AMI toward acute-on-chronic myocardial infarction. In a
first procedure, myocardial infarction by occluding the LAD was
induced. Over a 2- to 4-week period, the animals developed
anatomical and structural substrates, similar to those observed
in clinical chronic artery disease, due to the chronic infarction in
the LAD area. In a second procedure AMI was induced by LCx
occlusion and the arrhythmic effects could be investigated (71).
While open chest models have been crucial in understanding
AMI-induced arrhythmias, they come with several limitations:
thoracotomy and subsequent opening of the pericardium
influences thoracic pressure, cardiac filling and blood pressure
and the surgery itself can lead to global ischemic preconditioning.
In contrast, when percutaneous angioplasty is performed, the
thorax and pericardium can be left intact, allowing for more
stable hemodynamic conditions (72, 73). Further, anatomical
limitations in choice of coronary occlusion site, such as vessels
on the posterior side of the heart or intramural vessels, can
be overcome.
Infarct Location, Size, and Collaterals
Infarct location and occlusion sites within the coronary arteries
can alter the incidence of ectopic beats and ventricular
arrhythmias. Variation of occlusion site in the LAD in a porcine
model (30) and anatomical variations of the LCx in an ovine
model resulted in varying infarcted areas and different incidences
of VF (31).
Since infarct size is dependent on the individual anatomical
variation of coronary vessels and on the presence of collaterals,
an important aspect when aiming for reproducible infarct sizes
is the presence and degree of collateral flow. Humans have a
well-developed network of coronary collaterals (74) that can
be recruited rapidly during acute ischemia when direct flow
is interrupted (75). Although only 20 to 25% of humans with
healthy coronary arteries have sufficient collateral flow to prevent
signs of myocardial ischemia during short vascular occlusions
(76), those with coronary artery disease or prior myocardial
infarction have a collateral flow that can be sufficient to prevent
myocardial ischemia during coronary occlusion (77). In both
humans and pigs it has been found that the degree of coronary
flow reduction has direct influence on ventricular electrical and
mechanical parameters (74, 78). Among animal models there is a
large diversity in collateral perfusion: Non-diseased pigs, rabbits,
and ferrets have low collateral flow. Dogs, cats, and guinea pigs,
on the contrary, have a high collateral flow (75, 79).
Differences between human and animal exist in evolution of
myocardial infarction within the myocardium at risk. Humans
experiencing AMI show significantly slower infarct progression
than animals (pigs, rats and dogs) with induced ischemia (80).
Species Differences in Large Animal
Models of AMI
Several different large animal models have been used over the
last few decades in the setting of AMI and VF, during which
some have become more popular than others. A PubMed search
in May 2019 on studies conducted in dogs, pigs, sheep or
primates found 448, 77, 9, and 7 publications, respectively [MeSH
search terms used: “myocardial infarction” AND “ventricular
fibrillation” AND (“dogs” OR “swine” OR “sheep” OR “primates
NOT hominidae”)].
Dog
Dog models have provided deep insights into the complex
electrophysiological processes and arrhythmias during AMI (32).
The cardiac electrophysiology of the dog quite closely resembles
that of man. Its anatomy and distribution of Purkinje fibers
is similar to humans, providing a similar sequence of cardiac
activation and ventricular depolarization, as can be observed
in the ECG (54). However, ventricular repolarization shows
marked differences in dogs, with much greater variability and
inhomogeneity of repolarization across the ventricular wall (55,
81). The dog heart has been found to possess a rich collateral
circulation (82), in contrast to pigs and humans, with the
exception of patients with coronary artery disease. Recently,
the use of dogs has been restricted by animal welfare laws,
accompanied by rising expenses and the publications including
dogs in the field have consequently declined markedly.
Pig
Pigs are widely used since their cardiovascular system in general,
and the anatomy of the heart in particular, resembles that of
the human. Despite the similarities, Landrace pigs with similar
size to humans are only adolescents; full-grown adults weigh
several 100 kg. In contrast to Landrace pigs, minipigs show slower
growth rates accounting for amore stable heart/body weight ratio
(83) and providing amore cost-effective option, especially in long
term experiments (84). Cardiac similarity of pig to man is evident
in many aspects, such as structure, electrical properties, and
metabolic response to AMI (85). Since collateral flow is largely
absent in pigs, a close modeling of AMI with a more controlled
and solid infarct zone is possible (75). There are differences
in electrical properties, Purkinje fibers and propagation speed
of ventricular excitation (86). Pigs have a higher number of
Purkinje fibers, spreading almost completely from endo- to
epicardium, which is different to the predominantly endocardial
presence in humans. Purkinje fibers have a 5–10 times higher
conduction velocity compared to humans, leading to narrower
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QRS complexes when compared to humans (87). This results
in a different orientation in excitation of the ventricles (87),
which may impact the onset and maintenance of ventricular
arrhythmias, especially during later phases of VF (88). In
addition, when compared to humans, pigs show higher VF
thresholds upon electrical stimulation (89).
Sheep
Hearts of sheep have fairly similar anatomical characteristics
and physiological function as those of man. Their coronary
circulation, as well as the anatomy of their conduction system is
comparable to that of humansmaking sheep an interestingmodel
for human AMI (90–92). However, only a few studies addressing
AMI have been performed on sheep.
Non-human Primates
Whereas some earlier studies tried to exploit the close genetic
similarity of non-human primates to man by using rhesus
monkeys and baboons in AMI research (93, 94), today the use of
monkeys is very limited. This is mostly due to logistical, ethical
and monetary difficulties. LAD occlusion in unanaesthetized
rhesus monkeys provoked cardiovascular response similar to
man. VF was seen in 3/9 individuals (94). Additionally,
despite close anatomical resemblance to humans, the hearts of
these monkey species are small and have much faster sinus
rhythm than man, making them less favorable in respect to
electrophysiological resemblance (54).
PHARMACOLOGICAL TARGETS
Despite survival rate being markedly decreased in AMI patients
experiencing VF before or during primary PCI (8, 10) the
prophylactic use of antiarrhythmic drugs is not recommended
in the latest ACC/AHA guideline on STEMI therapy from 2013
in lack of effective therapy options (95). Only initiation of beta
blocker therapy within 24 h after AMI onset is recommended as
it has beneficial effects on VT/VF occurrence (96). However, AMI
leads to a variety of pro-arrhythmic changes that can potentially
pose pharmacological targets.
In the following section, amiodarone, save and effective in
arrhythmia protection in the setting of AMI, and new drugs or
experimental compounds in the setting of AMI induced VF that
have been tested in large animal models or humans are reviewed.
Drugs that have been proven harmful to human patients, like
the class Ic antiarrhythmic drugs encainide and flecainide (97)
or the class III drug d-sotalol (98) are not discussed here. An
overview is given in Table 1. It is noteworthy that nearly all tested
drugs were applied either before AMI was induced or during
VF, while almost no experiment or clinical studies tested drug
effects immediately after AMI but before coronary blood flow
could be re-established. The temporal relationship between drug
and ischemia can be crucial when aiming for translatability as the
drug in human patients will not at all, or in lower concentrations,
be present in the infarcted myocardium. The importance of this
temporal relationship was shown for the class 1b agent aprindine
were pre-treatment with the drug resulted in higher rates of VF
during AMI than treatment applied after onset of AMI (117).
Amiodarone
Amiodarone is believed to be one of the most effective
antiarrhythmic drugs for the treatment of a variety of different
arrhythmias. Effects of amiodarone differ between acute and
chronic treatment. In acute treatment the drug inhibits inward
Na+ and Ca2+ currents and outward K+ currents (IKr, IKs, IK,Ach,
and IK,Na) (118) and has non-competitive beta blocking effects
(119). Acute intravenous applications mainly lead to slowing
in atrioventricular conduction and have only mild effects on
the effective refractory period and little effect on QTc intervals,
whereas chronic treatment slows conduction in almost all cardiac
tissues and prolongs QTc interval (118).
Treatment with amiodarone has been tested in a variety
of animal models before and after AMI, as well as during
VF. Overall, animal models showed reduced ventricular
arrhythmia (100–102), decreased dispersion (103) and improved
defibrillation success rate (99). We showed reduced VF incidence
rates with amiodarone when given 10min after AMI onset (64).
In humans, little evidence is available for the prophylactic use
of amiodarone in the acute setting of AMI since randomized
trials mainly looked at unselected OHCA cohorts (120, 121). As
reported in a multicenter study on 3,026 patients, survival in
OHCA patients was not improved by the use of amiodarone or
lidocaine (a Na+ channel blocker) when administered during
VF (104). Yet data from a retrospective analysis focusing on
VT and VF during AMI suggest a positive effect of treatment
with amiodarone or lidocaine on survival (122). No randomized
trials in humans, investigating prophylactic treatment with
amiodarone after onset of AMI to prevent VT/VF in the early
phase, exist.
NHE1 Blockage
The Na+/H+ exchanger of subtype 1 (NHE1) is an important
proton-extruding mechanism in cells including cardiomyocytes
(123). During AMI, intracellular pH decreases due to anaerobic
metabolism, leading to an activation of NHE1 (124). Exchange
of the excessive proton load for Na+ causes intracellular Na+
accumulation that could indirectly affect the activity of other
ion transporters, particularly the NCX, which may lead to
ventricular arrhythmogenicity.
Pharmacological NHE1 inhibition in AMI animal models
has only assessed pre-treatment (105–107). These reports
showed reduced VF incidence (105, 106) without changes in
other ventricular arrhythmias (105), and eliminated reperfusion
induced AP shortening (107). In humans, NHE1 inhibition
during AMI has not been assessed.
KATP Channel Blockers
The ATP-sensitive K+ (KATP) channels generate an inwardly
rectifying outward current that is activated when the intracellular
ATP concentration is low, such as during AMI. KATP activation
during myocardial ischemia is partly responsible for the
abbreviation of the ventricular AP and protects the heart
from damage during ischemia by preventing Ca2+ build-up
(125). KATP channels may represent an intriguing inhibitory
target for antiarrhythmic therapy by reducing AMI-induced
AP shortening. In several large animal studies, inhibition of
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TABLE 1 | Studies conducted on pharmacological targets in first acute myocardial infarction to prevent ventricular fibrillation including species and temporal relationship
between drug treatment and ischemia.
Drug/Target Number of
animals,
species and
study
Treatment
before AMI
Treatment <
1h after AMI
Treatment >
1h after AMI
Treatment
during VF
Outcome
Amiodarone 60 dogs (99) X Amiodarone together with adrenaline and lidocaine improved
defibrillation success rate compared to adrenaline and lidocaine alone
114 sheep (100) X Amiodarone together with lidocaine decreased lethal arrhythmia
18 dogs (101) X Amiodarone suppressed ventricular arrhythmia (given 24 h after AMI)
24 dogs (102) X Amiodarone suppressed ventricular premature beats and VT (given
24 h after AMI)
24 dogs (103) X Amiodarone prolonged AP duration and decreased dispersion. 10
mg/kg decreased vulnerability to rapid ventricle stimulation, while 20
mg/kg increased it
18 pigs (64) X Amiodarone prevented VF, given 10min after AMI onset
3,026 humans
(104)
X No difference on 30 day mortality for amiodarone, lidocaine, or
placebo
NHE1 blockage 16 dogs (105) X HOE642 reduced VF incidence, the occurrence of premature beats or
VT was unchanged.
19 pigs (106) X Continuous infusion of HOE642 before and during AMI reduced VF
incidence from 9/11 pigs to 0/8 pigs.
13 pigs (107) X Cariporide removed AP shortening during reperfusion, 10min after
AMI
KATP channel
blockers
14 pigs (108) X HMR1893 attenuated AP shortening during AMI and reperfusion and
improved excitation propagation during AMI
15 dogs (109) X 5-hydroxydecanoate attenuated AP shortening during AMI and
reperfusion and improved excitation propagation during AMI
68 pigs (110) X Thiazolidinedione drugs attenuated AP shortening during AMI. The
treatment with rosiglitazone or HMR-1098 resulted shorter median
time to VF (29 vs. 6min)
121 pigs (111) X Thiazolidinedione drugs shortened time to VF, reduced defibrillation
success rate, attenuated conduction slowing and shifted ECG power
spectra during VF to higher frequencies. The same effects were seen
with glyburide but not 5- hydroxydecanoate
Gap-junction
modifiers
62 dogs (112) X Rotigaptide increased gap junctional conductance and prevented
induction of VT
20 pigs (113) X Rotigaptide decreased defibrillation threshold and fibrillation amplitude
in electrically induced VF. Return of circulation after defibrillation was
not improved
If current blocker 54 pigs (114) X Ivabradine reduced heart rate, reduced AP shortening and increased
VF threshold
80 pigs (115) X Ivabradine delayed the time to onset of ischemia-induced VF
22 pigs (116) X Repetitive episodes of 1-min ischemia were used. Ivabradine
increased regional myocardial blood flow
AMI, acute myocardial infarction; VF, ventricular fibrillation; VT, ventricular tachycardia; AP, action potential; NHE1, sodium-proton-exchanger of subtype 1; KATP, Adenosine
triphosphate-sensitive potassium channel; If , funny current.
KATP suppressed AMI-induced AP shortening (108–110) and
improved excitation propagation (108, 109), however, time to VF
was shortened (110, 111). This suggests that the protective effect
of preventing intracellular Ca2+ build-up outweighs any possible
anti-arrhythmic effect of reducing AP shortening.
Gap-Junction Modifiers
Cardiac gap-junctions, with connexin 43 (Cx43) as their main
isoform, provide communication and connections between
cells, allow the exchange of small molecules, and play an
important role in the propagation of electrical excitation
in the heart (126). Gap junction inhibition during AMI
reduces conduction velocity and increases defibrillation
thresholds (127). In contrast, gap junction modifiers, such
as rotigaptide, increase conduction velocity by increasing
functional coupling of gap junctions at the intercalated disc
(128). Rotigaptide prevented programmed stimulation-induced
reentrant VT during MI (112) and decreased defibrillation
threshold during prolonged VF (113). This, however, did
not translate to improved rates of return of spontaneous
circulation (113). Mitochondrial Cx43 is involved in the
energy metabolism in the heart (129) and Ca2+ handling
(130). Affecting these processes could produce unwanted
side effects.
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If Current Blockers
Sinus node tissue shows spontaneous depolarization by a
complex interaction of multiple inwardly and outwardly directed
ion currents, including the funny current (If). This current
is carried primarily by the hyperpolarization-activated cyclic
nucleotide-gated (HCN4) channels primarily conducting Na+.
In the setting of AMI, extra-nodal If in the left ventricle can be
increased leading to proarrhythmic tendencies (131).
Ivabradine selectively blocks the If current in a use-dependent
manner, resulting in reduced heart rate without negatively
affecting hemodynamics (132). Ivabradine pre-treatment in AMI
reduced heart rate, increased VF threshold and prevented AP
shortening in the ischemic area without changing myocardial
contractility (114). Ivabradine also delayed the time to ischemia-
induced VF by preserving myocardial metabolic energy status
(115) and lowering heart rate (116).
Autonomic Modulation
Besides pharmacological interventions on ion channels,
techniques to modulate autonomic dysfunction in AMI
by increasing vagal activity and reducing sympathetic
hyperactivation are arising (133). The different techniques
have been reviewed recently by Lai et al. (134). Briefly, vagal
activity can for example be increased by the tragus nerve,
carotid baroreceptor and vagus nerve stimulation, sympathetic
activity can for example be decreased by spinal cord stimulation,
stellate ganglion denervation or neuromodulation and renal
sympathetic denervation.
Modulation of the sympathetic nervous system by renal
denervation reduces ventricular ectopy and VF in a porcine
model of AMI. During reperfusion AP shortening and
spontaneous arrhythmias were not affected by this modulation
of the autonomic nervous system (135). Direct stimulation of
cervical pre-ganglionic parasympathetic fibers activates overall
cardiac vagal tone (136). Vagal stimulation, performed shortly
after the onset of an acute ischemic episode in conscious animals
with a healed MI, can effectively prevent VF independent of
heart rate reduction (137). Spinal cord stimulation also has an
antiarrhythmic effect on spontaneous non-sustained VT and
sustained VT during ischemia-reperfusion in association with a
reduction of repolarization alterations independent of any effect
on infarct size (138) .
SUMMARY AND CONCLUSION
AMI complicated by VF is one of the most common causes of
SCD while treatment options still remain limited. Even if SCD is
averted, VF in AMI patients is associated with decreased survival
rates. Several risk factors like sex, family history, life style factors
and alcohol consumption are known from epidemiological
studies. As studying AMI-induced VF is difficult in humans, large
animal models provide an important translational approach to
study AMI complicated by VF.
A variety of large animal models resembles human cardiac
physiology and can be used to investigate mechanisms of risk
factors or new treatment modalities. There are several important
factors to take into account when studying spontaneous VF
during AMI: the animal with its specific cardiac anatomy and
electrophysiology; the anesthesia and its effect on heart rate
and autonomic regulation; and the method, size and location of
coronary occlusion and the resulting ischemic area.
Although a number of promising pharmacological treatment
regimens such as KATP blockers, gap-junction modifiers, If
channel blockers, and NHE1 blockers have been investigated in
large animal models, the applied experimental design is often
insufficient to be successfully translated into clinical trials. Many
of the experiments evaluating new antiarrhythmic drugs are
performed pre-treatment before AMI onset, thereby results in
drug accumulation also in the infarcted area. This can both lead
to electrical and metabolic stabilization or destabilization of the
infarcted area. For a successful translation into clinical studies it
is of importance to adjust the experimental design according to
human situation.
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